Clinical trials · Washington, D.C., DC
Metastatic Cancer clinical trials in Washington, D.C.
We’re tracking 242 recruiting metastatic cancer studies with a site in or near Washington, D.C. — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT06350097RecruitingPhase 3
Osimertinib with or without datopotamab deruxtecan for first-line EGFR-mutant lung cancer
This trial tests a combination of two targeted drugs (osimertinib plus datopotamab deruxtecan) against osimertinib alone in patients with a specific type of lung cancer called EGFR-mutant non-small cell lung cancer. It is for people with advanced or recurrent disease who have not yet received systemic treatment.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04787744RecruitingPhase 2/Phase 3
Test standard prostate cancer treatment with or without targeted spot radiation
This study tests whether adding targeted local treatment (like radiation to a few spots seen on scans) improves outcomes for some people with limited (oligometastatic) prostate cancer. It compares standard systemic therapy alone versus standard therapy plus PET-scan–guided spot treatment.
Washington D.C., District of ColumbiaAges 18 years+ - NCT03678025RecruitingPhase 3
Standard treatment for metastatic prostate cancer, with or without local treatment
This Phase 3 trial studies whether using the usual medicines for metastatic prostate cancer, plus a definitive local treatment to the prostate, improves outcomes. It may help determine if treating the prostate directly can benefit people whose cancer has not worsened after initial hormone-based treatment.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06422143RecruitingPhase 3
Keytruda with or without Sac-TMT for advanced squamous lung cancer
This trial tests the combination of pembrolizumab (Keytruda) with or without a new drug, sacituzumab tirumotecan (Sac-TMT), as initial treatment for advanced squamous non-small cell lung cancer. It aims to see if adding Sac-TMT after initial treatment helps keep cancer under control longer.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05983432RecruitingPhase 1
Study of BL-B01D1 for advanced lung and other solid tumors
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
Washington D.C., District of ColumbiaAges 18 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06792695RecruitingPhase 2
Study of new treatments for colorectal cancer
This trial tests new treatment combinations for colorectal cancer that has spread (metastatic). It is for people whose cancer is mismatch repair proficient (pMMR) or microsatellite stable (MSS) and who have not had previous treatment for metastatic disease.
Washington D.C., District of ColumbiaAges 18–130 - NCT07038343RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial tests a new drug called AVZO-1418, either alone or with other treatments, for people with advanced solid tumors that have spread or cannot be removed. The goal is to see if the drug is safe and effective against certain types of cancer.
Washington D.C., District of ColumbiaAges 18–75 - NCT06863272RecruitingPhase 1/Phase 2
Study of ifinatamab deruxtecan for advanced prostate cancer
This trial tests a new drug, ifinatamab deruxtecan, either alone or in combination with other treatments, for men with metastatic castrate-resistant prostate cancer that has worsened despite hormone therapy. It aims to see if this approach can help shrink or slow the cancer.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07680764RecruitingPhase 2
Imzokitug plus pumitamig and chemo for first-line advanced lung cancer
This trial tests a new combination of drugs (imzokitug, pumitamig, and platinum-doublet chemotherapy) as a first treatment for advanced or metastatic non-small cell lung cancer that has not spread to the brain. The goal is to see if adding imzokitug makes the standard treatment work better.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05786924RecruitingPhase 1/Phase 2
Targeted cancer drug study for RAS/RAF mutation-positive tumors
This Phase 1/2 study tests S241656 (a targeted cancer medicine) in people whose cancers have certain “RAS/RAF” gene changes. It may help shrink tumors or control cancer growth, and also finds the safest dose and best way to use the drug.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07227168RecruitingPhase 1
Study of STRO-004 for advanced solid tumors
This trial tests a new drug called STRO-004 for people with advanced solid tumors (cancers that have spread or come back). It aims to see if the drug is safe and effective for those who have already tried other treatments.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06796543Recruiting
Radiation for young patients with sarcoma that has spread
This trial tests whether targeted radiation can help children and young adults with sarcoma that has spread to a few spots in the body. It's for those who are newly diagnosed (Stratum A) or whose sarcoma has come back or worsened (Stratum B).
Washington D.C., District of ColumbiaAges Up to 39 years - NCT04038502RecruitingPhase 2
Comparing carboplatin and olaparib for prostate cancer with BRCA gene changes
This study compares two treatments for prostate cancer that has spread and has specific gene changes (BRCA or related genes). It aims to see which treatment works better for people whose cancer has stopped responding to other hormone therapies.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06906562RecruitingPhase 2
Pemigatinib for advanced pancreatic cancer with FGFR changes
This trial tests a targeted pill, pemigatinib, for people with advanced pancreatic cancer that has a specific FGFR gene change. The study is done entirely through telemedicine, so you can participate from home if eligible.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07291037RecruitingPhase 3
Comparing a new drug to standard chemo for advanced lung cancer
This trial tests a new drug called datopotamab deruxtecan against a standard chemotherapy (docetaxel) for people with a certain type of advanced lung cancer (non-squamous non-small cell lung cancer) that has already been treated. The new drug targets a protein called TROP2 found on cancer cells, which may help slow or stop the cancer's growth.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05254171RecruitingPhase 2/Phase 3
Trial adds SBP-101 to standard chemo for pancreatic cancer
This trial studies whether adding SBP-101 to standard chemotherapy (gemcitabine plus nab-paclitaxel) can improve outcomes in people with metastatic pancreatic cancer. You may be eligible if you have not yet started treatment for metastatic disease and meet other health and test requirements.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06931340RecruitingPhase 3
Adding chemo to hormone therapy for advanced prostate cancer
This trial is for men with metastatic prostate cancer that has already spread beyond the pelvis. It tests whether adding a chemotherapy drug (docetaxel) to the usual hormone therapy plus apalutamide can help control the cancer better than hormone therapy alone.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06925737RecruitingPhase 3
Study of I-DXd for metastatic prostate cancer
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with metastatic prostate cancer that has stopped responding to hormone therapy. It may help by targeting and destroying cancer cells in a different way.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05673148RecruitingPhase 2
Adding targeted tumor treatment to standard therapy for limited metastatic colorectal cancer
This trial tests whether adding a precise, targeted treatment to destroy remaining cancer spots (called total ablative therapy) after initial chemotherapy can improve outcomes for people with limited metastatic colorectal cancer. It aims to see if this extra treatment is safe and effective.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05919264RecruitingPhase 1/Phase 2
FOG-001 for advanced solid tumors with certain gene changes
This trial tests a new drug, FOG-001, alone or with other treatments, for people with advanced solid tumors that have specific changes in the WNT pathway genes. It aims to see if the drug can shrink tumors or slow their growth.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06667076RecruitingPhase 2
Amivantamab combinations for advanced EGFR-mutant lung cancer
This trial tests two treatment combinations for people with a specific type of advanced lung cancer that has an EGFR mutation. One group gets amivantamab plus lazertinib, and the other gets amivantamab plus chemotherapy. The goal is to see which combo works better.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06706076RecruitingPhase 1/Phase 2
Experimental pill for lung cancer with EGFR or HER2 changes
This study tests an experimental pill that targets cancer cells with certain gene changes (EGFR or HER2). It may help shrink tumors or slow the cancer's growth in people with advanced non-small cell lung cancer.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07357597RecruitingPhase 4
Preventing mouth sores during breast or lung cancer treatment
This trial tests whether a steroid mouthwash can prevent mouth sores caused by the drug Datopotamab Deruxtecan (Dato-DXd). It is for people with certain types of advanced breast cancer or lung cancer who are about to start Dato-DXd for the first time.
Washington D.C., District of ColumbiaAges 18 years+
Hear when a new Metastatic Cancer trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Metastatic Cancer trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting metastatic cancer studies listed above.
- MedStar Georgetown University Hospital · 6 studies
- Research Site · 4 studies
- Georgetown University Medical Center · 3 studies
- Johns Hopkins University · 3 studies
- NEXT Virginia · 3 studies
- Sibley Memorial Hospital · 3 studies
- George Washington University · 2 studies
- MedStar Washington Hospital Center · 2 studies
What taking part in a metastatic cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there metastatic cancer clinical trials near Washington, D.C.?
- Yes. We're currently tracking 242 recruiting metastatic cancer studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic cancer study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic cancer studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.